Number of participants who achieved adequate occlusion as assessed by the independent core lab report of the target aneurysm at 1 year without retreatment was reported. Adequate occlusion was defined as the achievement of a Modified Raymond-Roy classification of the aneurysm at 1 year without retreatment. Modified Raymond-Roy Classification scale is a system used to grade the angiographic results of endovascular treatment of brain aneurysms. Class I represents complete obliteration of the aneurysm. Class II indicates residual neck, defined as persistence of a portion of the original arterial wall defect without opacification of the aneurysmal wall. Class III is subdivided into IIIa and IIIb: Class IIIa refers to residual aneurysm filling with contrast opacification within the coil interstices, whereas Class IIIb denotes residual aneurysm filling with contrast outlining the aneurysm wall.

Per protocol (PP) analysis set consisted of participants in the safety analysis set who (1) met the eligibility criteria, (2) had been treated with at least 75% GALAXY/MICRUSFRAME coils by length, and (3) completed a 1-year Digital Subtraction Angiography (DSA) /Magnetic Resonance Angiography (MRA). Here 'N' (overall number of participants analyzed) signifies number of participants who were evaluable for this outcome measure.

Packing density was defined as the ratio of the volume of coils to the volume of the coiled part of the aneurysm achieved during the procedure. Packing density is expressed as percentage.

Per protocol (PP) analysis set consisted of participants in the safety analysis set who (1) met the eligibility criteria, (2) had been treated with at least 75% GALAXY/MICRUSFRAME coils by length, and (3) completed a 1-year Digital Subtraction Angiography (DSA) /Magnetic Resonance Angiography (MRA).

Number of participants with complete occlusion at 1 year was reported as assessed by the independent core lab was reported. Complete occlusion was defined as achieving Modified Raymond-Roy I classification at 1 year, as assessed by the independent core lab. Modified Raymond-Roy I or II Classification scale is a system used to grade the angiographic results of endovascular treatment of brain aneurysms. Class I represents complete obliteration of the aneurysm. Class II indicates residual neck, defined as persistence of a portion of the original arterial wall defect without opacification of the aneurysmal wall. Class III is subdivided into IIIa and IIIb: Class IIIa refers to residual aneurysm filling with contrast opacification within the coil interstices, whereas Class IIIb denotes residual aneurysm filling with contrast outlining the aneurysm wall.

Per protocol (PP) analysis set consisted of participants in the safety analysis set who (1) met the eligibility criteria, (2) had been treated with at least 75% GALAXY/MICRUSFRAME coils by length, and (3) completed a 1-year Digital Subtraction Angiography (DSA) /Magnetic Resonance Angiography (MRA). Here 'N' (overall number of participants analyzed) signifies number of participants who were evaluable for this outcome measure.

Recanalization rate is defined as number of participants with recanalization. Recanalization was defined as a worsening in aneurysm occlusion grading using the Modified Raymond-Roy Classification (MRRC) scale. MRRC scale is a system used to grade the angiographic results of endovascular treatment of brain aneurysms. Class I represents complete obliteration of the aneurysm. Class II indicates residual neck, defined as persistence of a portion of the original arterial wall defect without opacification of the aneurysmal wall. Class III is subdivided into IIIa and IIIb: Class IIIa refers to residual aneurysm filling with contrast opacification within the coil interstices, whereas Class IIIb denotes residual aneurysm filling with contrast outlining the aneurysm wall.

Per protocol (PP) analysis set consisted of participants in the safety analysis set who (1) met the eligibility criteria, (2) had been treated with at least 75% GALAXY/MICRUSFRAME coils by length, and (3) completed a 1-year Digital Subtraction Angiography (DSA) /Magnetic Resonance Angiography (MRA). Here 'N' (overall number of participants analyzed) signifies number of participants who were evaluable for this outcome measure.

Number of participants with mRS 0-2 with unruptured aneurysm was reported. The Modified Rankin Scale (mRS) is a 7 point measure of functional outcome ranging from 0 to 6, where higher scores indicate greater disability. A score of 0 reflects no symptoms, 1 denotes no significant disability despite minor symptoms, 2 indicates slight disability with independence in personal affairs, 3 corresponds to moderate disability requiring some help but able to walk unassisted, 4 represents moderately severe disability with dependence for bodily needs and inability to walk alone, 5 signifies severe disability requiring constant care, and 6 indicates death. Increasing scores indicate worsening outcomes.

Per protocol (PP) analysis set consisted of participants in the safety analysis set who (1) met the eligibility criteria, (2) had been treated with at least 75% GALAXY/MICRUSFRAME coils by length, and (3) completed a 1-year Digital Subtraction Angiography (DSA) /Magnetic Resonance Angiography (MRA). Here 'N' (overall number of participants analyzed) signifies number of participants who were evaluable for this outcome measure.

Number of participants with any retreatment (surgical or endovascular) was reported. Retreatment is defined as any type of additional treatment (surgical or endovascular) of the target aneurysm after the index procedure.

Per protocol (PP) analysis set consisted of participants in the Safety Analysis Set who (1) met the eligibility criteria, (2) had been treated with at least 75% GALAXY/MICRUSFRAME coils by length, and (3) completed a 1-year Digital Subtraction Angiography (DSA) /Magnetic Resonance Angiography (MRA).

An adverse event (AE) is defined as any untoward medical occurrence, unintended disease or injury, or untoward clinical signs (including abnormal laboratory findings) in participants, users or other persons, whether or not related to the investigational medical device and whether anticipated or unanticipated. A serious adverse event (SAE) is defined as an adverse event that led to death, led to serious deterioration in the health of the participant, users, other persons as defined by one or more of the following: a life-threatening illness or injury, or a permanent impairment of a body structure or a body function including chronic diseases, or in-patient or prolonged hospitalization, or medical or surgical intervention to prevent life-threatening illness or injury or permanent impairment to a body structure or a body function led to fetal distress, fetal death or a congenital abnormality or birth defect including physical or mental impairment.

Safety analysis set consisted of all enrolled participants in whom coil treatment was attempted as defined by advancement of a coil outside of the distal end of the microcatheter inside the participant.